SCHEMBL841267

SCHEMBL841267

O=Cc1ccccc1OBOc1ccccc1C=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
HPGD P15428 1/20 0.59
HTT P42858 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
KMT2A Q03164 4/20 0.55
LMNA P02545 3/20 0.55
GAA P10253 1/20 0.55
MEN1 O00255 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
THRB P10828 1/20 0.52
BLM P54132 1/20 0.52
SRC P12931 2/20 0.52
PTGDR2 Q9Y5Y4 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 1/20 0.43
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2754990 0.83 ALDH1A1 (0.61) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL3426313 0.81 ALDH1A1 (0.44) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL1785881 0.79 ALDH1A1 (0.42) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL4434944 0.78 LMNA (0.75) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL524771 0.77 ALDH1A1 (0.43) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL2277795 0.77 CA1 (0.56) ALDH1A1HPGDHTTSMN1; SMN2LMNA
SCHEMBL9639641 0.76 LMNA (0.72) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL31599172 0.76 LMNA (0.72) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL904503 0.75 LMNA (0.39) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL23829688 0.74 ALDH1A1 (0.61) ALDH1A1HPGDHTTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
WO-2022159439-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2022-07-28 WO claimed
EP-4729525-A1 NEWLY SYNTHESIZED BORON-NITROGEN HETEROCYCLES AND THEIR CONJUGATES WITH PHARMACEUTICALLY UTILIZABLE SUBSTANCES Julius-Maximilians-Universität Würzburg (DE) 2026-04-22 EP disclosed
CN-120131677-A In-situ synthesis method of medicine and application thereof 北京大学 2025-06-13 CN disclosed
US-12043634-B2 Metal complexes, methods of making the same, and uses thereof THE UNIVERSITY OF MANITOBA (CA) 2024-07-23 US disclosed
US-20240174663-A1 PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS KING'S COLLEGE LONDON (GB) 2024-05-30 US disclosed
EP-4301751-A1 PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS King's College London (GB) 2024-01-10 EP disclosed
CN-116808285-A Tea polyphenol hydrogel and preparation method and application thereof 五邑大学 2023-09-29 CN disclosed
WO-2022185057-A1 PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS KING'S COLLEGE LONDON (GB) 2022-09-09 WO disclosed
CN-114727954-A Wet packed soft hydrogel ocular inserts 爱尔康公司 2022-07-08 CN disclosed
US-11271164-B2 Compound, composition, organic electroluminescent element and electronic device IDEMITSU KOSAN CO., LTD (JP) 2022-03-08 US disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 EP disclosed
EP-0938471-A1 THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS American Cyanamid Company (US) 1999-09-01 EP disclosed
US-5929097-A INHIBIT TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AMERICAN CYANAMID COMPANY (US) 1999-07-27 US disclosed
WO-1999032454-A1 NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1999-07-01 WO disclosed
WO-1999026921-A1 SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 1999-06-03 WO disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed
WO-1998053817-A1 BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 1998-12-03 WO disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 WO disclosed
WO-1998016503-A2 THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1998-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043634-B2 Metal complexes, methods of making the same, and uses thereof SOD1, CA2, SLC6A6 ALDH1A1 1422/4885HPGD 2065/4885HTT 753/4885
US-20240174663-A1 PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS HCN2, HCN1, HCN3 ALDH1A1 1933/4885HPGD 88/4885HTT 375/4885
US-11271164-B2 Compound, composition, organic electroluminescent element and electronic device PAX2, CXXC4, XDH ALDH1A1 4357/4885HPGD 3993/4885HTT 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.